Table 3:
Patients characteristics of the total population participated in the second surveillance in 2021.
| Total (N = 2353) | |
|---|---|
| Longitudinal cohort/new cohort (n) | 1733/620 |
| Age (years) | 65.6 ± 12.3 |
| Female | 1 124 (47.8) |
| BMI before dialysis (kg/m2) | 24.1 ± 4.4 |
| BMI after dialysis (kg/m2) | 23.2 ± 4.3 |
| HBsAg (+), n/N | 257/2352 (10.9) |
| Anti-HCV (+) | 292 (12.4) |
| HCV RNA (+) | 15 (0.6) |
| HCV RNA log (IU/mL)a | 5.4 ± 1.3 |
| WBC (×1000/µL) | 6.6 ± 2.6 |
| Hemoglobin (g/dL) | 10.6 ± 1.3 |
| Platelet count (×1000/µL) | 184.2 ± 62.5 |
| AST (U/L) | 17.6 ± 11.6 |
| ALT (U/L) | 15.5 ± 13.0 |
| Albumin (g/dL) | 3.9 ± 0.4 |
| Diabetes, n/N | 1164/2350 (49.5) |
| Hypertension, n/N | 1533/2350 (65.2) |
| Dyslipidemia, n/N | 658/2350 (28.0) |
| Cerebrovascular disease, n/N | 215/2350 (9.1) |
| Cardiovascular disease, n/N | 856/2350 (36.4) |
| Systemic lupus erythematosus, n/N | 43/2350 (1.8) |
| Hepatocellular carcinoma, n/N | 37/2349 (1.6) |
| Other malignancy, n/N | 217/2349 (9.2) |
Data are expressed as mean ± standard deviation or n (%).
a n = 15.
BMI: body mass index; longitudinal cohort: patients who participated in both first surveillance in 2019 and second surveillance in 2021; WBC: white blood cell.